Earnings Ahead

CRNX - Crinetics Pharmaceuticals

17.97 -0.37 -2.02

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals

About

Profile


Headquarters

California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

CRNX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Crinetics says FDA didn’t clear Phase 2 study request for hyperinsulinism drug
  • Crinetics Pharmaceuticals GAAP EPS of -$0.78 beats by $0.03, revenue of $0.46M beats by $0.26M
  • Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
  • Crinetics hormone CRN04894 therapy shows promise in early-stage study
  • Crinetics Pharmaceuticals GAAP EPS of -$0.73 misses by $0.17, revenue of $3.13M misses by $2.07M
  • Crinetics Pharmaceuticals prices $125M stock offering
  • Crinetics stock gains on hyperinsulinism candidate's trial data; JMP raises PT
  • Crinetics Pharmaceuticals reports results
  • Crinetics shows dose-dependent effect of hyperinsulinism candidate in early trial
  • Crinetics delays early Phase 1 data for experimental therapy due to COVID-19
  • Crinetics, Sanwa ink licensing deal for cancer/hormonal disorder drug in Japan
  • Crinetics Pharmaceuticals EPS misses by $0.03
  • Crinetics Pharmaceuticals prices $150M in stock offering
  • Crinetics drops after announcing common stock offering
  • Crinetics posts preliminary results from early-stage CRN04777 hyperinsulinism study
  • Crinetics Pharmaceuticals names Jeff Knight as chief operating officer
  • Crinetics Pharmaceuticals EPS misses by $0.10
  • Crinetics Pharmaceuticals posts positive data from early-stage CRN04894 trial
  • Crinetics Pharmaceuticals proposes $15M in private placement with Frazier Healthcare
  • Crinetics doses first patient in late-stage oral paltusotine acromegaly trial

Earnings History

Date EPS / Forecast Revenue / Forecast
November 5, 2021 -0.73 / -0.716 - / -
August 10, 2021 -0.7 / -0.6104 - / -
May 17, 2021 - / -0.575 - / -
May 6, 2021 -0.69 / -0.66 - / -
March 30, 2021 -0.66 / -0.578 - / -
November 17, 2020 - / -0.58 - / -
November 6, 2020 -0.56 / -0.526 - / -
August 7, 2020 -0.53 / -0.55 - / -
May 8, 2020 -0.71 / -0.63 71K / - Beat!
March 9, 2020 -0.6 / -0.68 321K / 130K Beat!
November 12, 2019 -0.6 / -0.57 505K / 150K Beat!
August 13, 2019 -0.51 / -0.46 100K / 187.5K
May 13, 2019 -0.37 / -0.41 367K / 130K Beat!
March 13, 2019 -0.35 / -0.43 781K / 175K Beat!
Date Price Open High Low Vol Change ER
Sep 14, 2023 29.28 28.82
30.13
28.47
3.0M 2.59%
Sep 13, 2023 28.54 30.59
30.75
28.52
7.1M -6.7%
Sep 12, 2023 30.59 27
31
26.94
11.1M 17.29%
Sep 11, 2023 26.08 25.08
29.45
24.75
24.8M 63.31%
Sep 8, 2023 15.97 16.16
16.21
15.76
617K -1.18%
 
Sep 7, 2023 16.16 16.53
16.58
15.99
723K -2.53%
Sep 6, 2023 16.58 16.97
17.1
16.4
612K -1.19%
Sep 5, 2023 16.78 17.35
17.7
16.71
596K -3.78%
Sep 1, 2023 17.44 17.5
18.05
17.4
931K 0.69%
Aug 31, 2023 17.32 17.13
17.89
16.92
634K 4.84%
Aug 30, 2023 16.52 16.49
16.69
16.36
395K 0%
Aug 29, 2023 16.52 17
17
16.5
550K -2.99%
Aug 28, 2023 17.03 17.11
17.36
16.87
289K -0.29%
Aug 25, 2023 17.08 17.38
17.38
16.76
410K -0.64%
Aug 24, 2023 17.19 17.98
17.98
17.11
500K -4.5%
Aug 23, 2023 18 17.75
18.35
17.51
996K 3.57%
Aug 22, 2023 17.38 16.11
17.43
15.95
823K 8.29%
Aug 21, 2023 16.05 16.27
16.27
15.81
546K -0.56%
Aug 18, 2023 16.14 16.29
16.51
16.05
566K -0.43%
Aug 17, 2023 16.21 16.28
16.38
15.95
529K -0.37%
Aug 16, 2023 16.27 16.58
16.67
16.24
523K -2.69%
Aug 15, 2023 16.72 16.8
17.31
16.55
517K -0.71%
Aug 14, 2023 16.84 16.32
16.95
16.25
655K 2%
Aug 11, 2023 16.51 16.67
16.85
16.4
326K -1.67%
Aug 10, 2023 16.79 16.73
17.19
16.6
436K 0.66%
Aug 9, 2023 16.68 17.47
17.47
16.27
567K -3.58%
Aug 8, 2023 17.3 17.51
17.66
16.97
569K -3.89%
Aug 7, 2023 18 18.5
18.55
17.99
373K -3.74%
Aug 4, 2023 18.7 19.13
19.38
18.5
608K -2.6%
Aug 3, 2023 19.2 19.07
19.35
18.84
343K 0.16%
Aug 2, 2023 19.17 19.19
19.4
18.92
575K -1.44%
Aug 1, 2023 19.45 19
19.47
18.63
494K 2.37%
Jul 31, 2023 19 18.79
19.15
18.41
386K 1.12%
Jul 28, 2023 18.79 18.59
19.06
18.32
393K 1.79%
Jul 27, 2023 18.46 18.99
19.08
18.2
418K -2.12%
Jul 26, 2023 18.86 18.57
19.26
18.48
463K 1.40%
Jul 25, 2023 18.6 18.41
18.81
18.13
414K 0.32%
Jul 24, 2023 18.54 18.5
18.62
18.1
515K -0.91%
Jul 21, 2023 18.71 20.12
20.12
18.65
429K -6.45%
Jul 20, 2023 20 19.63
20.06
19.45
397K 1.99%
Jul 19, 2023 19.61 19.98
20.08
19.55
451K -1.65%
Jul 18, 2023 19.94 19.94
20.76
19.93
443K -0.1%
Jul 17, 2023 19.96 20.37
20.81
19.88
446K -2.01%
Jul 14, 2023 20.37 20.43
20.5
19.94
493K -0.54%
Jul 13, 2023 20.48 19.96
21.06
19.72
694K 2.55%
Jul 12, 2023 19.97 20.3
20.3
19.7
461K -0.5%
Jul 11, 2023 20.07 19.74
20.29
19.72
361K 1.62%
Jul 10, 2023 19.75 18.63
19.8
18.46
397K 5.73%
Jul 7, 2023 18.68 18.38
18.82
18.35
325K 1.63%
Jul 6, 2023 18.38 18
18.41
17.63
465K 2.11%
Jul 5, 2023 18 18.12
18.43
17.96
234K -0.22%
Jul 3, 2023 18.04 17.99
18.05
17.64
152K 0.11%
Jun 30, 2023 18.02 17.93
19.21
17.81
369K 1.18%
Jun 29, 2023 17.81 18.45
18.5
17.79
352K -3.42%
Jun 28, 2023 18.44 17.95
18.47
17.78
267K 2.62%
Jun 27, 2023 17.97 18.41
18.44
17.69
393K -2.02%
Jun 26, 2023 18.34 18.48
18.64
18.28
361K -0.92%
Jun 23, 2023 18.51 18.5
18.68
18.09
897K -0.43%
Jun 22, 2023 18.59 19.62
19.62
18.51
532K -5.63%
Jun 21, 2023 19.7 19.94
20.23
19.15
388K 0%